Corteria Pharmaceuticals
- Address
- 128 Rue La Boetie
Sponsor Overview
Specializations
Heart Failure and Cardiac Dysfunction
Corteria Pharmaceuticals focuses on chronic heart failure and worsening heart failure, with research activity centered on symptoms, fluid balance, and cardiac structure in patients with advanced cardiovascular disease.
- Natriuresis
- N-terminal pro B-type natriuretic peptide (NT-proBNP)
- Kansas City Cardiomyopathy Questionnaire (KCCQ) symptom burden
- Left atrial volume index (LAVi)
The sponsor’s heart failure portfolio includes work in both symptomatic deterioration and broader chronic disease management, reflecting a strong therapeutic interest in cardiac remodeling and congestion-related outcomes.
Metabolic and Weight-Related Disorders
Research activity also extends to obesity and body weight regulation, including studies involving healthy participants to support evaluation of subcutaneous treatment strategies relevant to metabolic disease.
- Obesity
- Body weight change
- Subcutaneous administration
This area links metabolic outcomes with cardiology-focused development, particularly where weight control and fluid status are clinically relevant.
Healthy Volunteer and Early Clinical Evaluation
Several studies involve healthy subjects, indicating interest in early human assessment of safety, tolerability, and pharmacokinetics for new therapeutic candidates.
- Safety and tolerability
- Pharmacokinetics
- Injection strategy optimization
These activities support clinical development in both cardiometabolic and endocrine-related treatment settings.
Peptide-Based Therapeutics
The funded trials include candidates such as COR-1167 and COR-1389, pointing to a development program built around novel peptide-based or receptor-targeted therapies for cardiovascular and metabolic indications.
- Corticotrophin releasing factor 2 pathway
- Subcutaneous dosing
- Cardiometabolic therapeutics
The research portfolio is concentrated on mechanisms relevant to heart failure physiology and treatment delivery in outpatient settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of COR-1167 Sodium in Patients with Worsening Heart Failure: A Randomized, Placebo-Controlled, Dose-Response Study |  Czechia Hungary Poland Romania Spain | Not Yet Recruiting |
| Evaluation of Safety, Tolerability, and Pharmacokinetics of COR-1389 in Obesity and Right Heart Failure in Healthy Participants |  Germany | Recruiting |
| Phase 1 Study on Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Chronic Heart Failure Patients |  The Netherlands | Not Recruiting |
| Randomized Study of Optimal Subcutaneous Injection Strategy for COR-1167 in Chronic Heart Failure | The Netherlands | Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 42 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases4 trials359 other sponsors
- 2.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
42 centres- Address
- Uzsoki Utca 29-41, 1145 Budapest
- Address
- Podmaniczky Utca 109, 1062 Budapest
- Address
- Avinguda De Josep Molins 29-41, 08906 L'hospitalet De Llobregat
- Address
- Nico Bolkesteinlaan 75, 7416 SE Deventer
- Address
- Jihlavska 340/20, Bohunice, 625 00 Brno
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Corteria Pharmaceuticals.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.